Relevant bibliographies by topics / 401/.9

Contents

  1. Journal articles
  2. Books
  3. Book chapters
  4. Conference papers

Academic literature on the topic '401/.9'

Author: Grafiati
Published: 29 July 2024
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '401/.9.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "401/.9"

1

Warren, David K., Katelin B. Nickel, Anna E. Wallace, Daniel Mines, Victoria J. Fraser, and Margaret A. Olsen. "Can Additional Information Be Obtained from Claims Data to Support Surgical Site Infection Diagnosis Codes?" Infection Control & Hospital Epidemiology 35, S3 (October 2014): S124—S132. http://dx.doi.org/10.1086/677830.

Full text
Abstract:
Objective.International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes are increasingly used to identify healthcare-associated infections, often with insufficient evidence demonstrating validity of the codes used. Absent medical record verification, we sought to confirm a claims algorithm to identify surgical site infections (SSIs) by examining the presence of clinically expected SSI treatment.Methods.We performed a retrospective cohort study, using private insurer claims data from persons less than 65 years old with ICD-9-CM procedure or Current Procedure Terminology (CPT-4) codes for anterior cruciate ligament (ACL) reconstruction from January 2004 through December 2010. SSIs occurring within 90 days after ACL reconstruction were identified by ICD-9-CM diagnosis codes. Antibiotic utilization, surgical treatment, and microbiology culture claims within 14 days of SSI codes were used as evidence to support the SSI diagnosis.Results.Of 40,702 procedures, 401 (1.0%) were complicated by SSI, 172 (0.4%) of which were specifically identified as septic arthritis. Most SSIs were associated with an inpatient admission (232/401 [58%]), and/or surgical procedure(s) for treatment (250/401 [62%]). Temporally associated antibiotics, surgical treatment procedures, and cultures were present for 84% (338/401), 61% (246/401), and 59% (238/401), respectively. Only 5.7% (23/401) of procedures coded for SSI after the procedure had no antibiotics, surgical treatments, or cultures within 14 days of the SSI claims.Conclusions.More than 94% of patients identified by our claims algorithm as having an SSI received clinically expected treatment for infection, including antibiotics, surgical treatment, and culture, suggesting that this algorithm has very good positive predictive value. This method may facilitate retrospective SSI surveillance and comparison of SSI rates across facilities and providers.
APA, Harvard, Vancouver, ISO, and other styles
2

Zelenetz, Andrew David, Deepa Jagadeesh, Nishitha M. Reddy, Anastasios Stathis, Huda S. Salman, Adam Steven Asch, Vaishalee Padgaonkar Kenkre, et al. "Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 7512. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.7512.

Full text
Abstract:
7512 Background: ME-401, a potent and selective oral PI3kδ inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938). 70 pts were treated; we report here results in FL. Methods: Pts with ECOG ≤2, no prior PI3K therapy and progression of disease (POD) after ≥1 prior therapy were initially enrolled in a dose escalation phase (60-180 mg) then in 60 mg expansion cohorts as monotherapy or in combination with rituximab. ME-401 was given initially on a daily continuous schedule (CS) until POD or unacceptable toxicity. An intermittent schedule (IS) on days 1-7 of a 28-day cycle was then evaluated after 2 cycles (n = 18) or ≥3 cycles (n = 9) of CS. Toxicity on CS managed by switch to IS. POD on IS managed by switch to CS. Results: 48 FL pts received ME-401 alone (n = 39) or with rituximab (n = 9). Median age 64.5 yrs. (range 38-81), median prior therapies 2 (range 1-10), 30 had ≥3 prior therapies and 25 were POD24. 28 pts remain on therapy with median follow-up of 9.3 months (range 0.5-22.5) and 20 discontinued: 9 POD, 4 adverse events (AEs), 4 withdrew consent, and 3 for stem cell transplant. Delayed (> Cycle 2) grade 3 immune related AEs (irAEs), primarily diarrhea/colitis and rash, reported in 9/30 (30%) on CS and 2/18 (11%) switched to IS after 2 cycles, with irAEs noted 15 and 18 days after switch. 4 pts with grade 3 irAEs had a drug holiday and corticosteroids then resumed ME-401 on IS without AE recurrence. Objective responses in 34/43 pts (79%) with follow-up disease assessment: 79% with ME-401 alone (including 26% morphologic/metabolic CR), 78% with ME-401 plus rituximab, 91% in POD24, and 75% in ≥3rd line therapy. 24/27 (89%) IS pts continue therapy, 20 on IS and 4 who switched to CS due to POD on IS, and 3 pts discontinued due to persistent POD after switch to CS. Conclusions: ME-401 achieves a high rate of durable responses in R/R FL. IS appears to reduce the incidence of irAEs and maintains responses. POD on IS can be salvaged by reverting to CS. A randomized study to evaluate ME-401 given by IS or CS is enrolling pts with R/R FL, with switch to IS for irAEs and switch to CS if POD on IS. Clinical trial information: NCT02914938. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
3

Rajagopalan, Prasanna, and Harish C. Chandramoorthy. "(2E)-2-Benzylidene-4,7-dimethyl-2,3-dihydro-1H-inden-1-one (MLT-401), a novel arylidene indanone derivative, scavenges free radicals and exhibits antiproliferative activity of Jurkat cells." Asian Biomedicine 13, no. 4 (March 31, 2020): 131–39. http://dx.doi.org/10.1515/abm-2019-0052.

Full text
Abstract:
AbstractBackgroundThe arylidene indanone scaffold has contributed many lead molecules in chemotherapeutic anticancer agent research.ObjectivesTo determine the oxidant-scavenging activities and antiproliferative activity of (2E)-2-benzylidene-4,7-dimethyl-2,3-dihydro-1H-inden-1-one (MLT-401), an arylidene indanone derivative.MethodsJurkat cells, primary lymphocytes, and Vero cells were treated with MLT-401. Antioxidant properties of MLT-401 were determined using 2,2-diphenyl-1-picrylhydrazyl (DPPH)-based, 2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS)-based, and ferric-reducing antioxidant potential (FRAP) assays. Inhibition of cell proliferation was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based assay. Nuclear status was determined using a DNA fragmentation assay, and cell cycle stage was analyzed by flow cytometry. Mitochondrial membrane enzyme activities were measured using colorimetric methods.ResultsThe antioxidant assays gave MLT-401 half maximal inhibitory concentration (IC50) values of 1611 nM (DPPH-based assay), 2115 nM (ABTS-based assay), and 1586 nM (FRAP assay). MLT-401 inhibited proliferation of Jurkat cells with a concentration for 50% of maximal inhibition of cell proliferation (GI50) of 341.5 nM, being 12- and 9-fold less than GI50 concentrations for normal lymphocytes and Vero cells, respectively. MLT-401 caused nuclear fragmentation and DNA laddering as seen by electrophoresis. Jurkat cells showed a time-dependent accumulation of sub G0/G1 cells after MLT-401 treatment. Mitochondrial membrane-bound Na+/K+ ATPase, Ca2+ ATPase, and Mg2+ ATPase activities were inhibited by MLT-401 in a dose-dependent manner.ConclusionMLT-401 possesses significant antiproliferative activity and scavenges free radicals released through mitochondrial membrane damage in a Jurkat cell line model of cancer cells. Further investigation of MLT-401 as a chemotherapeutic anticancer agent and development of other arylidene indanone analogues are warranted. A detailed elucidation of mechanistic pathways is required for further development.
APA, Harvard, Vancouver, ISO, and other styles
4

Forlini, Francesca. "Adaptation in the Age of Media Convergence, Johannes Fehrle and Werner Schäfke-Zell (eds) (2019)." Journal of Adaptation in Film & Performance 14, no. 1 (March 1, 2021): 125–28. http://dx.doi.org/10.1386/jafp_00046_5.

Full text
Abstract:
Review of: Adaptation in the Age of Media Convergence, Johannes Fehrle and Werner Schäfke-Zell (eds) (2019)Amsterdam: Amsterdam University Press, 232 pp.,ISBN 978-9-46298-366-3, h/bk, €99.00ISBN 978-9-04853-401-2, e/bk, €98.99
APA, Harvard, Vancouver, ISO, and other styles
5

Lawlor, Hannie. "Following Franco: Spanish Culture and Politics in Transition, Duncan Wheeler (2020)." International Journal of Iberian Studies 35, no. 2 (June 1, 2022): 210–12. http://dx.doi.org/10.1386/ijis_00075_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Coll-Vinent, Sílvia. "Fólica, Laura; Roig-Sanz, Diana; Caristia, Stefania (eds.). Literary Translation in Periodicals: Methodological challenges for a transnational approach." Quaderns. Revista de traducció 29 (May 12, 2022): 212–15. http://dx.doi.org/10.5565/rev/quaderns.75.

Full text
Abstract:
Fólica, Laura; Roig-Sanz, Diana; Caristia, Stefania (eds.)Literary Translation in Periodicals: Methodological challenges for a transnational approachAmsterdam; Filadèlfia: John Benjamins, 2020, 401 p.ISBN 978-90-272-0773-9
APA, Harvard, Vancouver, ISO, and other styles
7

Kachinsky, A. M., J. A. Dominov, and J. B. Miller. "Intermediate filaments in cardiac myogenesis: nestin in the developing mouse heart." Journal of Histochemistry & Cytochemistry 43, no. 8 (August 1995): 843–47. http://dx.doi.org/10.1177/43.8.7542682.

Full text
Abstract:
By using immunohistology combined with immunoblotting, cell culture, and RT-PCR, we show that the intermediate filament protein nestin is transiently expressed in the midembryonic mouse heart. Monoclonal antibody (MAb) Rat-401, known to react with nestin in neural and skeletal muscle cells, was also found to react with ventricular and atrial cells throughout the mouse heart from embryonic day 9 (E9) through E10.5. Both before (E8.5) and after (E11-adult) this brief period, staining with Rat-401 was absent from atrial and ventricular myocytes. To evaluate the specificity of staining with MAb Rat-401 in the heart, we used immunoblotting, cell culture, and RT-PCR to verify that the authentic nestin protein and mRNA were expressed in cardiomyocytes of the E10 mouse. Nestin expression is the first molecular marker for this distinct midembryonic period of heart development.
APA, Harvard, Vancouver, ISO, and other styles
8

Angelot-Delettre, Fanny, Arthur E. Frankel, Jen Sing Liu, Estelle Seilles, Sabeha Biichle, Bernard Drenou, Mark L. Jacobson, et al. "The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells." Blood 118, no. 21 (November 18, 2011): 2588. http://dx.doi.org/10.1182/blood.v118.21.2588.2588.

Full text
Abstract:
Abstract Abstract 2588 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive neoplasm derived from plasmacytoid dendritic cell precursors that involves the skin and invariably leads to aggressive leukemic dissemination (Garnache Ottou et al., 2007). The incidence is more frequent in men and elderly subjects, but BPDCN may occur in young adults and even in children. Current treatment options are not codified, and although conventional chemotherapy often induces an initial response, relapse is frequent and rapid. The prognosis is poor, with a median overall survival of 9–13 months whatever the initial presentation was. Allogeneic hematopoietic transplantation is currently the only potentially curative treatment, but this is not an option for most elderly patients. Therefore, there is an urgent need to develop novel therapies that can specifically target this tumor type. Since BPDCN cells express high levels of the interleukin-3 receptor (IL-3R) α-chain (CD123), we tested SL-401, a novel biologic conjugate that targets IL-3Rα (Konopleva et al. 2010 and Frolova et al. 2010), against 2 BPDCN cell lines (GEN2.2 and CAL-1) and 6 primary BPDCN cells isolated from 5 patients (P#1-5). Cells from P#2 were tested at diagnosis (#2d) and at relapse (#2r). A CD123+ cell line (TF-1/H-ras) sensitive to SL-401 and a CD123− cell line (Daudi) were used as controls. Cytotoxicity was assessed by MTT assay as well as flow cytometry (FC) after Annexin-V (AV) and 7-AAD staining. Primary BPDCN cells were cultured with IL-3 alone (to maintain survival) or IL-3 in combination with SL-401 for 24 h (FC) or 48 h (MTT) (Figure 1). All BPDCN cell lines and primary cells were found to be sensitive to SL-401 by MTT assay (Figure 1A). These results were confirmed by FC with a dose-dependent decrease in cell viability observed for the GEN2.2 and CAL-1 lines, (47 ± 10 to 2 ± 2%, n = 4, and 90 ± 7 to 11 ± 5%, n = 4, respectively) when treated with SL-401 compared to untreated cells (48 ± 9% and 88 ± 5%, for GEN2.2 and CAL-1 respectively). Cell viability decreased for all the 6 primary cells tested by FC (Figure 1B). The Daudi negative control cell line was resistant to SL-401 (Figure 1A), which confirmed SL-401 specificity.Figure 1.In vitro sensitivity of BPDCN cell lines (CAL-1 and GEN2.2) and primary cells from 5 BPDCN patients to SL-401 assessed by FC and MTT assays.Figure 1. In vitro sensitivity of BPDCN cell lines (CAL-1 and GEN2.2) and primary cells from 5 BPDCN patients to SL-401 assessed by FC and MTT assays. This is the first study evaluating the in vitro sensitivity of BPDCN using the IL-3R targeted drug candidate, SL-401, which is currently being evaluated in clinical trials of patients with acute myeloid leukemia (AML), myelodysplastic syndrome, and chronic myeloid leukemia. Importantly, the highest concentration of SL-401 evaluated in these in vitro studies was ten times lower than the peak plasma concentration achieved in AML patients (Frankel et al, 2008). Since all BPDCN patients evaluated to date express high levels of CD123 (Garnache Ottou et al, 2009), these results suggest that BPDCN patients may clinically benefit from SL-401 therapy. This new strategy should be evaluated in a clinical trial. A. Percentage of viable cells from BPDCN patients (#1, #4, and #5, n = 1) or of viable CAL-1 and GEN 2.2 cells (n = 3) assessed by MTT assay after incubation with different concentrations of SL-401 or without drug (cells only). Untreated cells were considered as 100% viable cells. The Daudi cell line (CD123−) was used as a negative control (n = 3). B. Percentage of viable cells (AV and 7-AAD negative, as measured by FC) after incubation with different concentrations of SL-401 or without drug (cells only) for 24 h. The histogram represents a mean of 3 (P#1), 4 (P#2d), and 6 (P#2r) independent experiments. Samples (P#3- 4, and- 5) were each tested once. Disclosures: Frankel: Stemline Therapeutics: Patents & Royalties, Research Funding. Jacobson:Stemline Therapeutics, Inc: Employment, stock Options. Cirrito:Stemline Therapeutics, Inc: Employment, Equity Ownership, Patents & Royalties. Brooks:Stemline Therapeutics, Inc: Employment, equity options.
APA, Harvard, Vancouver, ISO, and other styles
9

Miegel, Annekathrin, and Pius Engelbert. "Rezension von: Engelbert, Pius (Hrsg.), Willehelmi abbatis Constitutiones Hirsaugienses." Zeitschrift für Württembergische Landesgeschichte 72 (April 11, 2022): 665–66. http://dx.doi.org/10.53458/zwlg.v72i.2484.

Full text
Abstract:
Willehelmi abbatis Constitutiones Hirsaugienses. Hg. von Pius Engelbert unter Mitwirkung von Candida Elvert (Corpus consuetudinum monasticarum 15,1–2). Siegburg: Schmitt 2010. CLIII u. 1020 S. ISBN 978-3-87710-401-9. Geb. mit Umschlag. € 284,–
APA, Harvard, Vancouver, ISO, and other styles
10

Lane, Andrew A., Kendra L. Sweet, Eunice S. Wang, William B. Donnellan, Roland B. Walter, Anthony S. Stein, David A. Rizzieri, et al. "Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)." Blood 128, no. 22 (December 2, 2016): 215. http://dx.doi.org/10.1182/blood.v128.22.215.215.

Full text
Abstract:
Abstract Background: SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on acute myeloid leukemia (AML) blasts and AML cancer stem cells (CSCs), and a variety of additional hematologic malignancies. While conventional chemotherapy can induce remission in a majority of treatment-naive AML patients, relapse rates remain high. Outcomes are particularly poor when minimal residual disease (MRD), as determined by genetic and/or flow cytometric analyses, remains after therapy, with high rates of relapse and short disease-free survival. Conceivably, a therapy directed at lowering MRD burden may improve long-term outcomes. Given the association of MRD with CD123+ AML CSCs, SL-401 is being evaluated in patients with AML in first or second complete remission (CR1 or CR2, respectively) with high risk of relapse including persistent MRD. Preliminary results are reported here. Methods & Results: This multicenter, single-arm Phase 2 trial of AML patients in CR1 or CR2 with high risk of relapse includes a lead-in (stage 1) and expansion (stage 2). In stage 1, patients (MRD+ or MRD-) receive SL-401 as a daily IV infusion at 7, 9, or 12 ug/kg/day for days 1- 5 of a 28 day cycle in a 3x3 design. In stage 2, patients (MRD+ only) receive SL-401 at the dose determined in stage 1. Presence of MRD for eligibility requires either molecular (by cytogenetics, FISH, PCR, or next-generation sequencing of AML-associated mutations) or multiparameter flow cytometry (MFC) evidence of persistent abnormalities in the setting of morphologic CR. In stage 2, MRD assessment will include MFC of bone marrow aspirates conducted at a central laboratory for uniformity. Objectives include characterization of SL-401 safety with determination of the maximum tolerated or tested dose, and preliminary assessment of efficacy including changes in MRD burden and response duration. As of 7/27/16, stage 1 has been completed and stage 2 is open for enrollment. Nine patients (stage 1) received SL-401 (7 ug/kg, n=3; 9 ug/kg, n=3; 12ug/kg, n=3). The median age was 63 years (range: 51-78 years); 6 males and 3 females were treated; 8 patients were in CR1 and 1 patient was in CR2 at enrollment. The 12 ug/kg dose level was the highest tested dose with no DLTs; MTD was not reached. The most common treatment-related AEs, all grades, were thrombocytopenia (3/9; 33%) and hypoalbuminemia (3/9; 33%); the most common ≥ grade 3 treatment-related AE was thrombocytopenia (1/9; 11%); there was no DLT. Patients treated at all doses received 1+ to 5+ cycles (ongoing) of SL-401, including 3 MRD+ patients treated at 7 ug/kg (n=1) or 9 ug/kg (n=2) who received 1-5 cycles, and 1 MRD+ patient treated at 12 ug/kg who is receiving ongoing SL-401 for 4+ cycles. For all 3 patients treated at 12 ug/kg (MRD+, n=1; MRD-, n=2), 2 patients remain on SL-401 and have received 1+ and 4+ cycles (both ongoing); one other patient treated at 12 ug/kg discontinued the study because of infection unrelated to study drug. Notably, the one MRD+ patient treated at 12 ug/kg (ongoing at 4+ cycles) had marked MRD reduction as determined by MFC at the local institution; this patient is being considered for stem cell transplant (SCT). Conclusions: Stage 1 is complete without DLT or MTD, and stage 2 (expansion) is open to enroll AML patients in CR1 or CR2 who are MRD+ at the highest tested dose of 12 ug/kg. The safety profile has been similar to that observed in other SL-401 clinical studies, with no unexpected AEs. Targeting MRD with SL-401 has the potential to reduce this chemo-resistant cell population and offer improved long-term outcomes for AML patients in remission with high risk of relapse. Updated data will be presented. Clinical trial information: NCT02270463. Disclosures Lane: N-of-1: Consultancy; Stemline Therapeutics: Research Funding. Sweet:Pfizer: Speakers Bureau; Karyopharm: Honoraria, Research Funding; Incyte Corporation: Research Funding; Novartis: Consultancy, Speakers Bureau; Ariad: Consultancy, Speakers Bureau. Wang:Immunogen: Research Funding; Incyte: Speakers Bureau. Stein:Seattle Genetics: Research Funding; Amgen: Consultancy, Research Funding, Speakers Bureau; Stemline Therapeutics: Consultancy, Research Funding; Argios: Research Funding; Celgene: Research Funding. Carraway:Incyte: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding, Speakers Bureau; Baxalta: Speakers Bureau. Prebet:celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Chen:Stemline Therapeutics, Inc.: Employment, Equity Ownership. Lindsay:Stemline Therapeutics, Inc.: Employment, Equity Ownership. Shemesh:Stemline Therapeutics: Employment, Equity Ownership. Brooks:Stemline Therapeutics, Inc.: Employment, Equity Ownership, Patents & Royalties. Stone:Novartis: Consultancy; Juno Therapeutics: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy; Amgen: Consultancy; Celator: Consultancy; Karyopharm: Consultancy; Jansen: Consultancy; Pfizer: Consultancy; ONO: Consultancy; Merck: Consultancy; Roche: Consultancy; Seattle Genetics: Consultancy; Sunesis Pharmaceuticals: Consultancy; Xenetic Biosciences: Consultancy. Jabbour:ARIAD: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Research Funding; BMS: Consultancy. Konopleva:Cellectis: Research Funding; Calithera: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "401/.9"

1

C, Trueswell John, and Tanenhaus Michael K, eds. Approaches to studying world-situated language use: Bridging the language-as-product and language-as-action traditions. Cambridge, Mass: MIT Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

United States. Congress. Senate. Committee on Finance. IRA's, 401(k) plans, and other savings proposals: Hearing before the Committee on Finance, United States Senate, One Hundred Fourth Congress, first session, February 9, 1995. Washington: U.S. G.P.O., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1938-, Clifton Charles, Frazier Lyn 1952-, and Rayner Keith, eds. Perspectives on sentence processing. Hillsdale, N.J: L. Erlbaum Associates, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Transportation, California Legislature Senate Committee on. Transcript of proceedings, public hearing before the Senate Committee on Transportation, November 21, 1985, 9:30 a.m., San Francisco War Memorial and Performing Arts Center, Green Room, 401 Van Ness Avenue, San Francisco, California: Public transit financing. Sacramento, CA (Box 90, State Capitol, Sacramento 95814): May be purchased from Joint Publications Office, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Inc, NetLibrary, ed. The psychology of language: From data to theory. Hove, East Sussex, UK: Erlbaum, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Henkes, Kevin. Penny and her marble. New York, NY: Greenwillow Books, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Henkes, Kevin. Penny and her marble. New York, NY: Greenwillow Books, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

ill, Swiatkowska Gabriela, ed. My name is Yoon. New York: Frances Foster Books, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ontario. Employment Standards Act, 2000: Statutes of Ontario, 2000, c. 41 as amended by 2001, c. 9, sched. I, s. 1; 2002, c. 18, sched. J, s. 3; and 2004, c. 15 ; and regulations: Benefits Plans, O. Reg. 286/01; Building services providers, O. Reg. 287/01; Enforcement, O. Reg. 289/01, as amended by O. Reg. 142/03; Exemptions, special rules and establishment of minimum wage, O. Reg. 285/01, as amended by O. Reg. 361/01 and O. Reg. 401/03; Posting of information concerning rights and obligations, O. Reg. 290/01; Termination and severance of employment, O. Reg. 288/01; Terms and conditions of employment in defined industries, O. Reg. 291/01. Toronto: Ministry of Labour, Operations Division, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dahle, Stefanie. Box Erdbeerinchen Erdbeerfee Mini 40 Exemplare : Besteht aus je. 10 Ex. 978-3-401-70260-5, 978-3-401-70261-2, 978-3-401-70262-9, 978-3-401-70263-6. Arena Verlag GmbH, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "401/.9"

1

Franckland, Francis. "401 Francis Franckland James Fort, Accra, 9 July 1681." In The Local Correspondence of the Royal African Company of England, 1681–1699, Vol. 1: The English in West Africa, 1681–1683, edited by Robin Law, 163. British Academy, 1997. http://dx.doi.org/10.1093/oseo/instance.00103641.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schloss, Irving S., and Deborah V. Abildsoe. "What Alternative Does TIAA-CREF Offer to Its Annuities?" In Understanding TIAA-CREF, 143–48. Oxford University PressNew York, NY, 2001. http://dx.doi.org/10.1093/oso/9780195131970.003.0033.

Full text
Abstract:
Abstract Although TIAA-CREF is oriented toward annuities, one significant alternative to the annuity does exist within the TIAA-CREF universe. It will dominate much of the discussion in part V. Mandated by Congress and called the Minimum Distribution Option by TIAA-CREF, this payment method tracks the legal requirements contained in Sec-tion 401(a)(9) of the Code and the Proposed Regulations thereunder. The Internal Revenue Service has indicated that one can treat these regulations as though they were final, and they play a critical role in formulating an estate plan where a TIAA-CREF and/or any other types of retirement account (treating multiple plans as though they were one) constitute the largest asset.
APA, Harvard, Vancouver, ISO, and other styles
3

Wjatscheslav, Anissimov, Behrens Stefan, and Heß Ines. "§9." In LADEMANN, Umwandlungssteuergesetz, 401–20. Richard Boorberg Verlag GmbH & Co KG, 2022. http://dx.doi.org/10.5771/9783415072367-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"9,...-----,...-------,--.,...----r-.,-----..--------,--..,..-------.--..,....------." In Geotechnical Engineering, 821. CRC Press, 2002. http://dx.doi.org/10.1201/9781482275858-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Case of Noguera et al. v. Paraguay. Merits, Reparations and Costs. Judgment of March 9, 2020. Series C No. 401." In Inter-American Yearbook on Human Rights / Anuario Interamericano de Derechos Humanos, Volume 36 (2020) (VOLUME II), 1380–415. Brill | Nijhoff, 2021. http://dx.doi.org/10.1163/9789004509924_006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Piketty, Thomas. "Kapitel 9. Ungleichheit der Arbeitseinkommen." In Das Kapital im 21. Jahrhundert, 401–46. C.H.Beck, 2014. http://dx.doi.org/10.17104/9783406671326-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jacoby, Florian, Michael Hinden, and Jan Kropholler. "Titel 9. Werkvertrag und ähnliche Verträge." In Bürgerliches Gesetzbuch, 401–43. Verlag C.H.BECK oHG, 2018. http://dx.doi.org/10.17104/9783406730573-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roth, Bettina. "§ 9 Art. 194 AEUV: Inhalt und Einordnung." In Sichere Energieversorgung im europäischen Mehrebenensystem, 401–42. Nomos Verlagsgesellschaft mbH & Co. KG, 2016. http://dx.doi.org/10.5771/9783845268071-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hartmann, Rainer, and Andreas Sprenger. "9 Vorsteuerabzug bei Reisekosten und ähnlichen Aufwendungen." In Reisekosten 2022, 401–2. Haufe Lexware, 2022. http://dx.doi.org/10.34157/9783648139271-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Müller-Graff, Peter-Christian. "§ 9 Das Recht des Binnenmarktes: Grundfreiheiten und Wettbewerbsordnung." In Europäisches Organisations- und Verfassungsrecht, 401–68. Nomos Verlagsgesellschaft mbH & Co. KG, 2022. http://dx.doi.org/10.5771/9783748908579-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "401/.9"

1

Gul, Mustafa, H. Burak Gokce, and F. Necati Catbas. "A Characterization of Traffic and Temperature Induced Strains Acquired Using a Bridge Monitoring System." In Structures Congress 2011. Reston, VA: American Society of Civil Engineers, 2011. http://dx.doi.org/10.1061/41171(401)9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Starets, O. O., I. Ye Shapovalenko, and T. M. Khimenko. "Features of metabolic associated fatty liver disease diagnostic criteria in children." In THE GREATEST HUMANKIND ACHIEVEMENTS IN HEALTHCARE AND VETERINARY MEDICINE. Baltija Publishing, 2024. http://dx.doi.org/10.30525/978-9934-26-401-6-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sinetova, M. A., Z. V. Krivova, R. A. Sidorov, A. S. Voronkov, M. S. Pakholkova, and M. O. Ivanova. "The dynamics of the accumulation of lipids and starch in three strains of green microalgae under nitrogen starvation." In IX Congress of society physiologists of plants of Russia "Plant physiology is the basis for creating plants of the future". Kazan University Press, 2019. http://dx.doi.org/10.26907/978-5-00130-204-9-2019-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tyshkovets, M. "Professional standards of teachers: experience of Ukraine and abroad." In Pedagogical comparative studies and international education – 2020: a globalized space of innovation. NAES of Ukraine; Institute of Pedagogy of the NAES of Ukraine, 2020. http://dx.doi.org/10.32405/978-966-97763-9-6-2020-398-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Marinković, Sanja, and Vlasta Đuranović. "401 Neurosurgical treatment of intractable epilepsies due to focal cortical dysplasia." In 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lyn-Cook, Lascelles E., Beverly Word, and George Hammons. "Abstract 401: Array analysis of cigarette smoke condensate (CSC) on gene promoter methylation in human lung cells." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hayashi, Hirotaka, Noriko Yonemoto, Fumiaki Hayashi, Kei Kamiutsuri, and Shunji Kobayashi. "#34113 Distal approaches of ultrasound-guided intercostal nerve block in patients with acute zoster-associated pain: A quantitative descriptive research." In ESRA Abstracts, 40th Annual ESRA Congress, 6–9 September 2023. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/rapm-2023-esra.401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '401/.9' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography